SciencemRNA Cancer Vaccine Halts Melanoma in Phase 3 TrialModerna and Merck's personalized mRNA vaccine stopped melanoma returning post-surgery in a landmark Phase 3 trial of 1,000 high-risk patients.
Human AchievementsFocal Therapy Beats Surgery Side Effects in Prostate TrialA 10-year trial of 3,500 men found focal therapy for prostate cancer matches surgery — and cuts the risk of serious side effects by about half.
